Hongene Biotech, ReciBioPharm Collaborate to Enhance Gene Editing, Drug Manufacturing Capabilities

Hongene Biotech, ReciBioPharm Collaborate to Enhance Gene Editing, Drug Manufacturing Capabilities

By, Admin 12 September 2024

Overview

Hongene Biotech Corporation, an end-to-end global leader for specialist nucleic acid manufacturing, offering a wide range of products to meet the needs of the life sciences industry in nucleic acid manufacturing, and ReciBioPharm, a leading advanced therapeutics CDMO services provider, have announced a strategic collaboration that will enhance gene editing drug manufacturing capabilities.

Hongene for Nucleic Acid Manufacturing

  • Hongene, renowned for its expertise in the nucleic acid manufacturing field, has recently pioneered a novel proprietary technology for sgRNA synthesis. 
  • This technique significantly diminishes impurities common in conventional production methods, thereby elevating product quality.

About ReciBioPharm

  • ReciBioPharm, with its state-of-the-art facilities near Boston, MA, is a provider of comprehensive CDMO services, including the integrated development, analytics, and GMP manufacturing of plasmid, mRNA, LNP, and sterile drug products. 
  • The company is also on the forefront of continuous manufacturing technology for mRNA-LNP products through its work with MIT and its grant from the FDA’s CBER office to provide faster readiness and reaction to new pandemic threats.

Impacts of Strategic Alliance

  • The strategic alliance between the two companies creates a unique solution for innovators in the gene editing field. 
  • ReciBioPharm will expand its service portfolio to include sgRNA manufacturing, utilizing Hongene’s innovative synthesis process, providing plasmid, mRNA, sgRNA, LNP, and fill-finish services in a single facility. 
  • This will streamline the entire development and manufacturing process, mitigating the logistical complexities of dealing with multiple CDMOs, and ultimately accelerating the path for drug development.

Words from the President: ReciBioPharm

Vikas Gupta, president of ReciBioPharm, stated, ""Our collaboration with Hongene Biotech marks an important step forward for ReciBioPharm, enabling us to offer comprehensive, seamless solutions in the rapidly evolving gene editing sector. The combination of Hongene’s high-quality raw materials and synthesis methods with our capabilities will provide our clients with an unmatched portfolio of services in this developing field.""

Words from the CEO: Hongene Biotech

Echoing the sentiment, Wei Jiang, CEO at Hongene Biotech, shares, ""Our partnership with ReciBioPharm is set to redefine the manufacturing space for gene editing. Our cutting-edge sgRNA synthesis technology, combined with ReciBioPharm's expertise in end-to-end mRNA and drug product manufacture, promises to bring a unique solution that has significant value to the healthcare field.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!